Skip to Main Content Menu Search Site

Barrett’s esophagus modeled in a human Organ Chip

Personalized Organ Chips lined by multiple tissues obtained from the same patient offer a new way to study Barrett’s esophagus with potential for better risk assessment and therapeutic developments

By Benjamin Boettner

Barrett’s esophagus modeled in a human Organ Chip
This immunofluorescence staining shows how an esophageal Organ Chip culture recapitulates the stroma-epithelial interphase of a Barrett’s esophagus (BE) region within a patient’s throat. The BE-like epithelium (visualized by a marker in their outer cell membranes in blue, and nuclei in magenta) grows immediately on a stroma-mimicking collagen gel with embedded fibroblasts (visualized for a fibroblast marker in yellow) that were derived from the same patient. Credit: Wyss Institute at Harvard University

(BOSTON) — Acid reflux, the backwash of stomach acid into the throat, or esophagus, is something that people many experience occasionally. But when it happens repeatedly and becomes a chronic problem, it can result in “Barrett’s esophagus” (BE), a condition in which cells in the epithelial lining of the esophagus appear to transform into stomach or intestine cells. This process is known as “metaplasia” and is associated with an increased incidence of esophageal cancer – one of the deadliest tumors estimated to be the sixth most common cause of cancer deaths worldwide.

To be able to predict which patients with Barrett’s esophagus are at an increased risk for developing cancer, and to discover drugs that could prevent this transition, a much better understanding of its cellular and molecular triggers is needed. However, animal models are not useful for studying BE, as they have a different esophageal anatomy, and existing in vitro models fail to replicate the changes in cell and tissue structure that are hallmarks of BE observed in human patients.

The esophagus is lined by a layer of epithelial cells that directly faces the esophageal lumen and is supported from below by a mixture of fibroblast cells and surrounding extracellular matrix known as “stroma.” In addition to providing mechanical and nutritional support, it is known that the stroma sends signals to the epithelial cells to guide their differentiation and function during development of the esophagus in the fetus. While the stroma continues to provide the esophageal epithelium with signals over a person’s lifetime to enable tissue renewal, their contribution to the metaplasia that often precedes cancer formation remains unknown.

Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University led by Wyss Founding Director Donald Ingber, M.D., Ph.D., in collaboration with researchers from McGill University in Montreal, Canada and University of California San Francisco (UCSF) has developed a model that recapitulates the responses of a BE epithelium to stroma-derived fibroblasts in a patient-specific manner in vitro using Organ Chip technology. Organ Chips are microfluidic cell culture devices in which key structures and functions of human organs composed of different cell and tissue types can be mimicked outside of the body.

The team created chips lined by epithelial cells that were directly grown on a stroma-like layer with embedded fibroblast cells recreating an actual in vivo-like epithelial-stroma interface. Importantly, both the epithelial cells and fibroblasts were isolated from different regions within the same esophagus from a patient with esophageal cancer; some regions appeared healthy, while others showed typical signs of BE, or had progressed to cancer. When they reconstituted the epithelial-stroma interface with epithelial cells and fibroblasts from a BE region, the cells reformed a tissue that strongly resembled BE tissue. But when they combined BE epithelial cells with fibroblasts from the cancerous regions, they observed that cells in the BE epithelial layer proliferated at a faster rate, and showed pre-cancerous changes under the microscope. The findings set the stage for in-depth analysis of the stroma-epithelial relationship in individual patients. They are published in Gastro Hep Advances.

Expanding the toolbox and personalizing it

In developing its BE Organ Chip model, Ingber’s team built on both previous Organ Chip models that they engineered to study the gastrointestinal system, including the colon, and organoid culture methods that they optimized for esophageal epithelial cells. Since patients’ stem cell potential and differentiation into functional epithelial cells are preserved in organoid cultures over an extended time, the researchers created a long-lasting source for primary human epithelial esophageal cells. “Many in vitro models of BE make use of patient cells that have been genetically manipulated to become immortalized, but they also lose some of their characteristics. Being able to apply primary human cells to Organ Chips allows us to stay much closer to the human situation,” said first-author Elee Shimshoni, Ph.D., who worked on the project as a Postdoctoral Fellow on Ingber’s team.

Barrett’s esophagus modeled in a human Organ Chip
The epithelium of a patient’s Barrett’s esophagus (BE) modeled in an Organ Chip, and grown directly on a stroma-mimicking matrix containing fibroblasts derived from the same BE-region shows obvious signs of BE. Stained in blue are mucus-producing goblet cells that in healthy conditions are only found in the intestine, and stained in purple are mucus molecules usually only produced in stomach. Credit: Wyss Institute at Harvard University

To mimic the human epithelium-fibroblast interactions and be able to observe them over an extended period of time, Shimshoni and her colleagues cultured the patient’s fibroblasts within a collagen gel resembling the cells’ natural extracellular matrix in the top channel of an Organ Chip that contains two parallel channels separated by a porous membrane. To facilitate direct contact between the two cell populations, the esophageal epithelial cells, taken from their organoid cultures, were grown on top of the fibroblast-containing collagen gel in the top channel. A removable lid on this Organ Chip version allowed the epithelial cells to be exposed to air at a so-called air-liquid interface, which is important for their complete differentiation and formation of a tight epithelial layer, just as it happens in the esophagus in vivo. Through the lower channel, liquid medium was continuously flowed to provide nutrients to the cultured cells.

When the researchers combined normal fibroblasts with normal epithelial esophageal cells from a healthy-appearing region in what they called a “homotypic pairing,” they observed the formation of a multilayered epithelium with normal esophageal cell morphology and composition, and normal molecular marker expression. On the other hand, a homotypic pairing of BE-associated fibroblasts with BE epithelial cells produced a BE-like epithelium with thicker epithelial cells of a more cuboidal shape and interspersed mucus-producing goblet cells usually found in the intestine. These findings showed that their culture system was able to recapitulate normal and BE esophageal tissue formation. However, “only when we paired the BE epithelial cells with esophageal cancer-associated fibroblasts from a cancerous site in the same individual’s esophagus in a ‘heterotypic pairing’ were BE epithelial cells pushed into a hyper-proliferative state typical of a pre-cancerous process – normal fibroblasts and BE-specific fibroblasts could not produce this effect when paired with BE epithelial cells,” said Shimshoni.

Potential for impacting patients’ lives

These models enable investigators to not only study the molecular and cellular basis of epithelial-stromal interactions that play key roles in the progression from metaplasia to cancer formation, but also interactions guiding normal esophagus development. “To our knowledge, this is the first in vitro system in which it is possible to analyze the heterogenous responses of BE epithelium to stromal cells from different regions of the same organ from the same patient,” said senior author Ingber. “This approach, if done for multiple patients, could allow us to identify early biomarkers of changes that are indicative of cancer progression, and perhaps even future therapeutic targets. It also has potential to be used to personalize the selection of therapeutics.” Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Bioinspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.

This approach, if done for multiple patients, could allow us to identify early biomarkers of changes that are indicative of cancer progression, and perhaps even future therapeutic targets. It also has potential to be used to personalize the selection of therapeutics.

Donald Ingber

Ingber’s team, spear-headed by Shimshoni, worked closely with the groups of Thea Tlsty, Ph.D. at UCSF, and clinical scientist Lorenzo Ferri, M.D., Ph.D. at the McGill University Health Centre in Canada. Ferri is the Head of the Center’s Division of Thoracic and Upper Gastrointestinal Surgery treating patients with esophageal and other cancers and malignancies and provided access to cell type-specific samples from a patient with esophageal cancer, while Tlsty has been extensively studying the contributions of stroma to wound healing and malignancies in multi-disciplinary approaches. The groups are part of a consortium that focuses on the key role that stroma plays in the progression of metaplastic tissues to cancers in various organs.

The study was also authored by additional members on Ingber’s team, including Gwenn Merry, Zachary Milot, Crystal Yuri Oh, Viktor Horvath, Russell Gould and Sean Hall; Tlsty’s team, including Joseph Caruso, Chira Chen-Tanyolac, and Philippe Gascard; Ferri’s team, including Veena Sangwan, Julie Bérubé, and Swneke Bailey; as well as Matthew Stachler, an Assistant Professor at UCSF. The study was supported by grants from Cancer Research UK (under award #C19767/A27145), and the National Institutes of Health (under award #P30DK034854).

Close menu